Overexpression of RUNX1 short isoform has an important role in the development of myelodysplastic/myeloproliferative neoplasms

Hiroko Sakurai; Yuka Harada; Yosuke Ogata; Yuki Kagiyama; Naoki Shingai; Noriko Doki; Kazuteru Ohashi; Toshio Kitamura; Norio Komatsu; Hironori Harada

doi:10.1182/bloodadvances.2016002725

Overexpression of RUNX1 short isoform has an important role in the development of myelodysplastic/myeloproliferative neoplasms

Blood Adv. 2017 Jul 31;1(18):1382-1386. doi: 10.1182/bloodadvances.2016002725. eCollection 2017 Aug 8.

Authors

Hiroko Sakurai¹, Yuka Harada^{1

2}, Yosuke Ogata², Yuki Kagiyama³, Naoki Shingai¹, Noriko Doki⁴, Kazuteru Ohashi⁴, Toshio Kitamura⁵, Norio Komatsu¹, Hironori Harada^{1

3}

Affiliations

¹ Department of Hematology, Juntendo University School of Medicine, Tokyo, Japan.
² Department of Clinical Laboratory Medicine, Bunkyo Gakuin University, Tokyo, Japan.
³ Laboratory of Oncology, School of Life Sciences, Tokyo University of Pharmacy and Life Sciences, Hachioji, Japan.
⁴ Tokyo Metropolitan Cancer and Infectious Disease Center Komagome Hospital, Tokyo, Japan; and.
⁵ Division of Cellular Therapy, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.

Abstract

RUNX1a, but not RUNX1b, is overexpressed in CD34⁺ cells from patients with myelodysplastic/myeloproliferative neoplasms.SRSF2P95H mutation induces RUNX1a overexpression and a monocytic phenotype in TF-1 cells.